Malaga Cove Capital LLC Has $649,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Malaga Cove Capital LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 42.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,837 shares of the medical research company’s stock after purchasing an additional 2,934 shares during the period. Malaga Cove Capital LLC’s holdings in Edwards Lifesciences were worth $649,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $28,000. First Community Trust NA bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $29,000. Webster Bank N. A. bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $39,000. Versant Capital Management Inc increased its position in shares of Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after purchasing an additional 326 shares in the last quarter. Finally, HHM Wealth Advisors LLC bought a new position in Edwards Lifesciences during the 2nd quarter valued at about $55,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,250 shares of company stock worth $2,746,988. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Trading Down 1.4 %

NYSE EW opened at $65.75 on Thursday. The stock has a market capitalization of $39.61 billion, a price-to-earnings ratio of 9.49, a PEG ratio of 3.74 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The stock’s 50 day moving average price is $67.75 and its two-hundred day moving average price is $77.18. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 22.56%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the firm earned $0.59 earnings per share. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on EW shares. Canaccord Genuity Group dropped their price objective on shares of Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating for the company in a report on Friday, October 25th. Barclays cut their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Jefferies Financial Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $85.00 to $70.00 in a research report on Wednesday, September 18th. Royal Bank of Canada dropped their target price on Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Finally, Oppenheimer reissued an “outperform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a report on Thursday, September 12th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.